The term 'neurogenic inflammation' refers to a series of proinflammatory responses produced by the stimulation of peripheral terminals of a subset of primary sensory neurons and the subsequent release of the neuropeptides, calcitonin gene-related peptide (CGRP) and the tachykinins, substance P (SP) and neurokinin A (NKA) [1] . The neurons that produce inflammation comprise a heterogeneous cell population with A-delta and C fibres, defined as polymodal nociceptors because they sense thermal, chemical and high-threshold mechanical stimuli. These neurons express on their plasma membrane a large panel of excitatory and inhibitory receptors and channels, and some of these signalling proteins have been successfully used as targets for analgesic or anti-inflammatory drugs. Among the channels expressed on peptidergic primary sensory neurons, transient receptor potential vanilloid-1 (TRPV1) [2] , activated by the xenobiotic capsaicin, the pungent ingredient of plants of the genus Capsicum, is of paramount importance. Capsaicin produces burning pain by stimulating TRPV1 and by releasing sensory neuropeptides causes neurogenic inflammation. However, high concentrations/doses of capsaicin have the ability, after an initial excitatory phase, to desensitise the sensory nerve terminals, thus reducing the transmission of sensory/pain signals and abolishing neurogenic inflammation [3, 4]. This specific feature of capsaicin has greatly contributed to define the role of this subset of sensory nerves in pathophysiological models of human diseases and has been Pierangelo Geppetti Jay Guido Capone Marcello Trevisani Paola Nicoletti Giovanni Zagli Maria Rosalia Tola Abstract For more than a century neurogenic inflammation has been proposed to have a role in various human diseases. The present review will cover the conceptual steps of the itinerary that has led to the conclusion that neurogenic inflammation is important in migraine. Of particular relevance for the object of this article is the observation that tachykinindependent neurogenic inflammatory responses are evident in rodents, but much less pronounced or absent in other mammal species, including man, whereas neurogenic vasodilatation, most likely mediated by CGRP, occurs in most mammalian species and also in man. Recent evidence that a CGRP receptor antagonist was effective in the treatment of migraine attack supports the hypothesis that neurogenic vasodilatation is a major underlying mechanism of migraine.
used as a therapeutic strategy in certain pain and inflammatory conditions [1] . From a large body of evidence accumulated in the last few decades, the general hypothesis has originated that neurogenic inflammation is the underlying mechanism in different human diseases, including migraine and other primary headaches [1] .
Neurogenic inflammation occurs mainly at the vascular levels, where in almost every organ of mammals it comprises CGRP-mediated arteriole vasodilatation and tachykininmediated plasma protein extravasation and leukocyte adhesion to the venule endothelium. In extravascular tissues, marked differences exist according to tissue and species. Thus, for example, in the airways tachykinins mediate an epithelium-dependent bronchodilatation in the mouse and rat, whereas in guinea pigs and man severe bronchoconstriction is produced [1] . In contrast with the guinea pig, in the urinary bladder of the rat the dilatation of the bladder produced by CGRP is absent, while tachykinin-mediated contraction prevails [1] . More recent evidence obtained with the advent of specific and high affinity antagonists for tachykinin and CGRP receptors have clarified that speciesdependent differences in neurogenic inflammation responses exist also at the vascular level. These differences have markedly influenced the process through which the knowledge of the contribution of sensory nerves and neurogenic inflammation in migraine has been developed.
Vascular components of neurogenic inflammation
Biological effects produced by tachykinins are mediated by three different heterotrimeric G-protein coupled receptors, the NK1, NK2 and NK3 receptors. These receptors are associated with Gq/11 proteins and their stimulation results in the mobilisation of Ca 2+ ions in the cytosol. Neurogenic plasma protein extravasation occurs at the level of postcapillary venules where SP and NKA, released from sensory nerve terminals, stimulate NK1 receptors on endothelial cells, thus increasing Ca 2+ mobilisation and activating intracellular contractile elements. The contraction causes the opening of gaps between endothelial cells, a phenomenon that allows the passage of macromolecules, including albumin, into the interstitial space and the formation of inflammatory oedema. Leukocyte adhesion to the venule endothelium, also mediated by NK1 receptor activation [5] , follows and potentiates the early inflammatory responses and is accompanied by mast cell degranulation and inflammatory mediator production. Evidence that trigeminal nerve stimulation results in plasma protein extravasation in the meninges of rodents suggested that this mechanism could be important for the clinical manifestation of migraine [6] . The observation that triptans blocked, presumably at a prejunctional site of action, neurogenic plasma extravasation, further corroborated the hypothesis [7] . The discovery of nonpeptidic, high affinity and selective NK1 receptor antagonists allowed the design of clinical studies aimed to verify whether NK1 receptor blockade could be beneficial in the migraine attack. However, more than one antagonist with a good pharmacodynamic and pharmacokinetic profile resulted non-effective in clinical trials [8, 9] .
A careful critical analysis of the features of neurogenic inflammation in man should have cast doubts regarding the effectiveness of NK1 blockers to ameliorate migraine headaches. Capsaicin administration to human skin causes a remarkable erythema and arteriolar vasodilatation [10] , presumably mediated by CGRP release, but there is little or no evidence that capsaicin causes cutaneous plasma extravasation. Whereas in man SP and NKA potently contract the bronchi and the urinary bladder, capsaicin does not. Finally, failure of capsaicin to release SP/NKA from human sensory nerve terminals in vitro has been reported [11] . From these findings it may be concluded that if the release of sensory tachykinins occurs in human tissues, this would not be sufficient to produce the biological effects commonly observed in rodents. In contrast, the observations that capsaicin application to the human skin produces a neurogenic flare response, most likely mediated by CGRP [10, 12] and that capsaicin releases CGRP from human tissues in vitro [11, 13] have important implications for our current understating of migraine mechanism and the treatment of migraine attack. Mechanistic studies in experimental animals and a recent clinical trial have corroborated the hypothesis that sensory CGRP and neurogenic inflammation have a central role in migraine pathogenesis.
Calcitonin-related peptides
In 1982, it was discovered that alternative processing of RNA transcripts from the calcitonin gene results in the production of distinct mRNAs encoding a 37-amino acid neuropeptide, called CGRP [14] . Whereas the calcitonin mRNA predominates in the thyroid, the specific mRNA for CGRP is abundant in the nervous system [15] . Subsequently, a human form of CGRP was isolated from thyroid tissue of patients with medullary thyroid carcinoma [16] . CGRP is now known to belong to a family that includes the more recently discovered peptides adrenomedullin (AM) and amylin. AM was isolated from human pheochromocytoma cells in 1993 as a 52-amino acid peptide, which was able to stimulate cAMP production in platelets [17] . Endothelial and vascular smooth muscle cells, especially upon stimulation with inflammatory cytokines, are among the many cell types that can produce AM [18] . The amyloid deposits in the pancreas of noninsulin-dependent diabetics [19] were the source of the 37-amino acid peptide, amylin, or islet amyloid polypeptide (IAPP), which shares some structural homology with CGRP and AM. Amylin is secreted with insulin from pancreatic β-cells after meals, and its major physiological effect is the regulation of glucose metabolism in the opposite manner to insulin with respect to glycogen synthesis and glucose uptake into muscle [20] .
CGRP peptides
The two isoforms of CGRP, α and β, are found in most species, differ by one and three amino acids, and exhibit similar functional activities [14, 16] . One of the two forms, αCGRP, encoded by the calcitonin gene, is the more abundant and found in discrete areas of the central and peripheral nervous system. In man, βCGRP, which differs from αCGRP by three amino acids, is primarily located within enteric nerves [21] and the pituitary gland [22] . The nerve growth factor (NGF) is of outmost importance in influencing plasticity of CGRP because it regulates the growth and maintenance of sensory nerve function [23] . The half-life of CGRP in the circulation is 7-10 min in the human plasma [24] . CGRP metabolism is not regulated by an identified proteolytic pathway and it is probably broken down via a number of routes. Efficient cleavage of CGRP into inactive fragments is produced by mast cell tryptase in the skin [25] , and matrix metalloproteinase II has the ability to metabolise CGRP and remove its vasodilator activity [26] , whereas CGRP is a poor substrate for neutral endopeptidase, so this pathway is probably less important as a route for CGRP degradation in peripheral tissues [27] .
CGRP and its receptor: a unique story
In the late 1980s, the existence of two receptors was originally proposed: CGRP1 and CGRP2, with the CGRP1 receptor being the predominant mediator of CGRP effects in the guinea pig or rat atrium, whereas the CGRP2 receptor activity was identified by the CGRP-induced inhibition of electrically evoked twitch responses in the rat vas deferens [28] . CGRP8-37, a 30-amino acid fragment of CGRP, behaves as an antagonist and shows a relative selectivity for the CGRP1 receptor [29] . Rat calcitonin receptor-like receptor (CL) was cloned in 1993 [30] . The 7 transmembrane domains human isoform of rat CL was cloned 2 years later and consists of 461 amino acids with 91 and 56% identity to the rat orphan calcitonin receptor-like sequence and the human calcitonin receptor, respectively [31] . Because this receptor did not bind CGRP in the cells studied, it was considered an orphan receptor. However, when the cDNA was expressed in human embryonic kidney 293 (HEK293) cells it exhibited specific, high-affinity binding sites for CGRP and displayed functional properties, including increase in cAMP production, similar to the human CGRP1 receptor [32] . However, because CL expression in COS-7 cells failed to produce a functional receptor, it was concluded that HEK293 cells must also possess a factor essential for the production of a functional receptor. The puzzle was solved after the discovery of the receptor activity-modifying protein (RAMP), a single transmembrane domain protein with 148 amino acids necessarily required to associate with CL to confer receptor activity [33] . Receptors for CGRP/AM that have been cloned and characterised so far consist of a seven-transmembrane G protein-coupled CL receptor in association with one of three single membrane-spanning RAMPs. RAMP1 associated with CL produces a CGRP receptor (CGRP1) that is antagonised by the CGRP antagonist CGRP8-37 (Table 1 ). In particular, it has been shown that 
CGRP receptor antagonists
Compound 1 showed a pKi of 7.8 in binding experiments on SK-N-MC as compared to 8.9 of CGRP8-37 [36] . SB-273779 is selective for the CGRP receptor but is less potent than BIBN4096BS, with a Ki value of 310±40 nM on SK-N-MC cells, and it also exhibited low potency in rat and porcine lungs [37] .
Prejunctional modulation of CGRP release
The release of sensory neuropeptides, including CGRP, undergoes a fine tuning by a series of mediators and agents that act at prejunctional receptors/channels on sensory nerve terminals. Evidence indicates a range of G protein-coupled receptors that include those for bradykinin, prostanoids, opioids, 5-hydroxytryptamine (5-HT1 receptor), histamine (H3 receptor), neuropeptide Y, somatostatin, vasoactive intestinal polypeptide, purines and galanin. Among the channels the TRPV1 is the best known and it can be activated by noxious temperatures, low extracellular pH and a series of lipid derivatives [2, [38] [39] [40] [41] . TRPV1 activity can be regulated by the stimulation of certain G protein coupled receptors (bradykinin and prostaglandins) or tyrosine kinase receptor (NGF) [42, 43] . Other pathophysiologically relevant agents may also regulate TRPV1. The recent observation that ethanol stimulates TRPV1 channels and releases CGRP, by lowering the threshold temperature for channel activation [44] , suggests that the ability of alcoholic beverages to trigger the migraine attack may be due to this neurogenic inflammatory mechanism. The presence of excitatory CGRP receptors on sensory neurons, within the dorsal root ganglia, which may act as stimulatory autoreceptors, has been reported recently [45] . Inhibition of CGRP release by α2-adrenoceptors, located presynaptically on sensory neurons [46] , and the ability of CGRP to inhibit the release of norepinephrine from sympathetic nerves [47] in the rat mesentery circulation, suggest that reciprocal interactions can occur between the noradrenergic constrictor system and the sensory (vasodilatatory) system, and are indicative of an important role for CGRP in the regulation of peripheral blood flow.
Arterial relaxation by CGRP
The vascular effects of CGRP appear most pronounced in the microvasculature. CGRP is one of the most potent vasodilator substances identified to date in the microcirculation, with a potency ~10-fold greater than the prostaglandins and 2-3 orders of magnitude greater than other classic vasodilators, including acetylcholine, adenosine, 5-HT and SP. The role of CGRP in the regulation of vascular tone in small vessels is underlined by the observation that CGRP-containing nerves can pass into the vascular smooth muscle layer in smaller arteries. CGRP released at these sites can have profound effects on arteriolar dilatation and on the microvasculature. Although CGRP-containing nerves also innervate venous tissues, its activity on this type of vessels has been less investigated. Current evidence indicates that administration of exogenous CGRP or the release of endogenous CGRP produces an NO-and endothelium-independent relaxation that correlates closely with a rise in intracellular cAMP, activation of protein kinase A (PKA), and activation of K + channels (Fig. 1) . The involvement of ATP-sensitive potassium channels [48] in the vasodilator mechanism of CGRP has been suggested and subsequently extended to channels sensitive to glibenclamide or charybdotoxin (large-conductance Ca 2+ -activated K + channels) in rat pial arterioles [49] . Exceptions to endothelium-independent relaxation to CGRP occur only in a few tissues, including the rat aorta, where the relaxation to CGRP depends on the presence of an intact endothelium and is attenuated by inhibitors of NO synthase, implying an NO-dependent mechanism [12, 50] . In human internal mammary artery [51] and rat pulmonary artery [52] , a similar endothelium-dependent mechanism of relaxation has also been seen. Evidence that CGRP activates phospholipase C in HEK293 cells, lead-ing to an increase in intracellular Ca 2+ via inositol trisphosphate (IP3) [53] suggests that this alternative intracellular pathway may be responsible for the CGRP-induced release of NO (Fig. 1) . Other peptides of the CGRP family may also produce vascular relaxation. There is evidence that AM acts to relax porcine coronary artery preconstricted with U46619 [54] . The vasodilator effects of amylin appear to be mediated by the CGRP1 receptor as they are blocked by CGRP8-37.
Migraine and neurogenic inflammation
Our current comprehension of the migraine mechanism is still incomplete. However, it is possible that genetic abnormalities initiate the alteration of the response threshold to migraine-specific triggers in the brain [55] . Studies using positron emission tomography have shown increased blood flow (an index of neuronal activity) during spontaneous migraine attacks in the cerebral hemispheres (cingulate, auditory and visual suppression areas) and suggest that the process driving the migraine attack and the area susceptible to the migraine triggers may be located in the brain stem [56] . Neural activation eventually results in the dilatation of cranial blood vessels including carotid arteriovenous anastomoses [57] . There is also evidence in experimental animals that the migraine aura, rather than from an ischaemic phenomenon, derives from an initial neuronal dysfunction and is probably the clinical manifestation of a cortical spreading depression [58, 59] . A reflex painful vasodilatation of the cranial blood vessels follows the cerebral oligaemia, and probably derives from activation of the trigeminal perivascular innervation [55, 57] .
Stimulation of trigeminal ganglia/sensory nerves is regarded as a necessary step for the process that produces pain and associated symptoms of the migraine attack. Trigeminal neurons may release neuropeptides and cause tachykinin-dependent plasma extravasation in cranial tissues, including the meninges and CGRP-dependent arterial vasodilatation. The hypothesis that neurogenic, tachykinin-mediated plasma protein extravasation could be the underlying mechanism of the migraine attack [6] gained support from the findings that specific antimigraine drugs, including sumatriptan, are able to suppress plasma extravasation produced by antidromic stimulation of trigeminal nerve terminals in the rodent meninges [7] . As mentioned before, this response is entirely mediated by tachykinin NK1 receptors localised on postcapillary endothelial cells. Thus, it was proposed that NK1 receptor antagonists could be beneficial in migraine treatment. However, various clinical trials showed that different NK1 receptor antagonists, including RPR100893 [9], GR205171 [60] or lanepitant [8], were not effective for Fig. 1 The drawing depicts the mechanisms by which CGRP is released from the terminal of TRPV1-expressing sensory neurons and produces arterial vasodilatation the acute treatment of the migraine attack or as pre-emptive treatment of migraine [61] . Although the failure could be due to a variety of pharmacokinetic or other reasons, unrelated to the role of neurogenic plasma extravasation in migraine pathogenesis, it is also possible that tachykinin release, activation of NK1 receptors and their action in neurogenic inflammation do not play any role in this disease.
In contrast, in recent years the hypothesis that the release of CGRP, which dilates cranial blood vessels and stimulates sensory nerve transmission, may have a key role in migraine mechanism, has obtained much attention and experimental support [62] . Trigeminal nuclei as well as non-myelinated trigeminal sensory nerve fibres express an abundant CGRPlike immunoreactivity and cerebral blood vessels are innervated by sensory nerves that store several neuropeptides amongst which CGRP is the most abundant [63] . A Ca 2+ -dependent and capsaicin-sensitive release of CGRP, but not SP, has been documented from human tissues containing non-trigeminal [13] or trigeminal [11] sensory nerve endings. Furthermore, plasma concentrations of CGRP, but not of SP, were elevated during the headache phase of migraine [64] and cluster headache [65] . There is evidence that intravenous infusion of CGRP produces a migraine-like headache [66] , and intravenous infusion of nitric oxide produces a migraine-like headache with an associated increase in plasma CGRP levels [67] . In migraine patients baseline CGRP levels were considerably higher, and the changes in plasma CGRP levels during migraine attacks were significantly correlated with the headache intensity [67] .
Action of drugs effective on neurogenic vasodilatation
Ergotamine and triptans have been proposed to abort migraine attacks by diverse mechanisms, including constriction of dilated cranial blood vessels and carotid arteriovenous anastomoses [68] , reduction of CGRP release from perivascular trigeminal nerve endings, and inhibition of nociceptive transmission on peripheral and central endings of trigeminal sensory nerves [55] . Similarly to rodents, human trigeminal ganglia/sensory nerves express abundant 5-HT1B/1D receptors [69] , thus strengthening the evidence in favour of the presynaptic inhibitory effects of triptans [62] . This effect of triptans results from the stimulation of the heterotrimeric G protein-coupled 5-HT1B/1D receptor that, by inhibiting adenylyl cyclase and cyclic adenosine monophosphate cytosol levels, reduces neural activity, including the neuropeptide release. The principle of inhibiting neuropeptide release from sensory nerve endings by reducing neuronal functioning represents the basis of the antimigraine action of the agonist of the inhibitory adenosine A1 receptor, GR79236 (N-[(2-methylphenyl)methyl]adenosine (metrifudil), 2-(phenylamino) adenosine). This compound, stimulating A1 receptors, inhibits neurogenic vasodilatation in rats [70] , trigeminal nociception and CGRP release in cats [71] , and trigeminal nociception in humans [72] . Pilot clinical studies have reported that GR79236 has antimigraine action, probably due to an inhibitory effect on nociceptive trigeminal neurons [70] . Despite these encouraging results, further studies are required to fully establish the efficacy and safety of adenosine A1 receptor agonists in migraine.
The adverse effects of triptans and the limitation of their use in patients with cardiovascular diseases derive from the ability of this type of drug to maintain the same vasoconstrictor activity. Selective agonists of the 5-HT1D receptor, such as PNU-109291 [(s)-3,4-dihydro-1-ethyl]-N-methyl-1H-2-benzopyran-6-carboximide) [73] or 5-HT1F receptors such as LY334370 (4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]-benzamide) [74] have been developed with the idea that they should exert an antimigraine effect by a prejunctional inhibition of neural activity, and should be devoid of any vascular constrictor action. However, PNU-142633 proved to be ineffective in the acute treatment of migraine [75] and LY334370 did show efficacy when used in doses which may interact with 5-HT1B receptors [74, 76] . Thus, further investigation is required to establish whether nonvasoconstrictor triptans or other compounds acting at prejunctional levels of terminals of primary sensory neurons are useful in the treatment of migraine and related headaches.
CGRP antagonists in migraine
The alternative approach to treat the migraine attack, by limiting neurogenic inflammatory vasodilatation, consists in the blockade of CGRP receptor by selective antagonists. The first peptide CGRP receptor antagonist, CGRP8-37, proved ineffective in migraine treatment [77] . However, its low potency and very short half-life [29] precluded any firm conclusion on the role of CGRP, its receptor and neurogenic vasodilatation in migraine mechanism. The discovery of the peptoid BIBN4096BS, an antagonist characterised by an exceedingly high affinity for the human CGRP receptor [35] , offered evidence in experimental animals that indicated that this drug is a suitable tool to prove the concept that CGRP exerts a pivotal role in the migraine pathogenesis. BIBN4096BS was found to reduce the vasodilatation induced by trigeminal stimulation in marmosets [78] , the vasodilator responses induced by capsaicin in porcine carotid, including carotid arteriovenous anastomotic dilatation, and CGRP-induced porcine carotid vasodilatation and arterial-jugular venous oxygen saturation difference [79] . Thus, BIBN4096BS could produce, at a postjunctional level (by CGRP receptor blockade), effects similar to those that triptans cause by reducing CGRP release, and that result in inhibition of CGRP receptor signalling. Indeed, triptans inhibit trigeminal CGRP release in animal experimental models [55, 63] , and clinical data show that sumatriptan normalised the elevated CGRP levels with alleviation of migraine [55] and cluster headache attack [65] . These findings have suggested that BIBN4096BS could be developed as an effective antimigraine drug.
A recent clinical trial has shown that BIBN4096BS is effective in the acute treatment of migraine without significant side effects or intrinsic vasoconstrictor effects [80] . The CGRP receptor antagonist at a dose of 2.5 mg was effective in the treatment of the migraine attack with a response rate of 66% as compared with 27% for placebo. BIBN4096BS also showed significant superiority over placebo in reducing the pain at 2 h and improving the nausea, photophobia, phonophobia, functional capacity and the time to meaningful relief [80] . Side effects were 25% with BIBN4096BS and 12% with placebo. The most frequent side effect was paraesthesia and no serious adverse effect was recorded. Intra-and extracranial vessels and systemic haemodynamics have been studied in man following BIBN4096BS administration. BIBN4096BS had no influence on global or regional cerebral blood flow and did not show any effect on systemic haemodynamics and adverse events were minor [81] . Thus, CGRP-receptor blockade does not seem to affect cerebral or systemic circulation in humans. From this finding it is possible to hypothesise that circulating CGRP in basal condition does exert a tonic vasodilatatory activity and the use of BIBN4096BS or other CGRP receptor antagonists should be without risk of cerebral or systemic vasospasm.
Conclusions
Growing evidence indicates inhibition of CGRP activity as a major avenue in the treatment of the migraine attack. Inhibition of neural activity that produces neuropeptide release from peripheral and central endings of peptidergic trigeminal neurons has been proposed as one of the key antimigraine actions of triptans. However, because these drugs reduce both tachykinin and CGRP release, the identity of the neuropeptide principally involved in migraine pathogenesis remained obscure. The uncertainty regarding the role of one specific neuropeptide mirrors the doubt regarding the component of neurogenic inflammation 
